Phoslyra (calcium acetate oral solution, 667 mg per 5 mL) is a phosphate binder (PB) indicated for the reduction of serum phosphorus in patients with end stage renal disease (ESRD). Phoslyra is administered orally with food.
IMPORTANT SAFETY INFORMATION:
- Phoslyra is contraindicated in patients with hypercalcemia.
- Patients should have serum calcium levels closely monitored and their dose of Phoslyra adjusted or terminated to bring levels to normal. No other calcium supplements should be given concurrently with Phoslyra.
- Phoslyra may decrease the bioavailability of tetracyclines or fluoroquinolones.
- There are no empirical data on avoiding drug interactions between calcium acetate or Phoslyra and most concomitant drugs. When administering an oral medication with Phoslyra where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug 1 hour before or 3 hours after Phoslyra or calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range.
- The most common (>10%) adverse reactions experienced with Phoslyra are hypercalcemia, nausea, and diarrhea. Of the observed drug-related adverse reactions, diarrhea (5/38, 13.2%) was more common with Phoslyra than with a solid formulation calcium acetate.
- Phoslyra may cause diarrhea with nutritional supplements that contain maltitol.
For additional important safety information, please see the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, call 1-800-FDA-1088, or call Fresenius Medical Care at 1-800-323-5188.
This information is intended for use by U.S. Healthcare Professionals only. Patients and Families click here.